Date of Award
Doctor of Philosophy
Molecular Biology, Microbiology and Biochemistry
As a posttranslational modification, the sumoylation pathway plays a key role in a wide variety of cellular events such as cell proliferation, differentiation, stress response, DNA repair and apoptosis. Given the important role of protein sumoylation, it is not surprising that alternation of sumoylation will ultimately affect cell growth as well as cancer development. As an essential E2 conjugating enzyme for sumoylation, Ubc9 plays a central role in sumoylation-mediated cellular pathways. In this study, we investigate the role of Ubc9 in drug resistance as well as its regulation in cancer cells. An early gene product, Gam1, encoded by the avian adenovirus CELO, is an inhibitory protein for the sumoylation machinery by degrading E1 and E2 enzymes. Given the suppressive effect of Gam1 on Ubc9, in this study, we use this protein to study the role of Ubc9 in drug resistance as well as its underlying mechanism. Besides showing suppression of Ubc9 expression and sumoylation by Gam1, we found that Gam1 caused significant cell growth inhibition. Of interest, like the Ubc9 dominant negative mutant, Gam1 also sensitized cells to DNA damaging agents such as topotecan and doxorubicin as well as non-DNA-damaging agents such as paclitaxel and vincristine. Furthermore, we elucidated that Gam1-mediated cell growth inhibition was associated with induction of apoptosis. In particular, Gam1 induced caspase-3 activity as detected by immunostaining and Western blot. Taken together, our findings suggest that activation of the caspase pathways is at least in part responsible for the increased apoptosis in Gam1-expressing cells and, thus, contributes to the growth inhibition and enhanced chemosensitivity. Available evidence suggests that Ubc9 is a tumor promoting factor. However, little is known about the regulation of Ubc9. In this study, we first show that Ubc9 is overexpressed in several types of cancers, highlighting its clinical significance. We then investigate the underlying mechanism of Ubc9 upregulation. Of interest, we present evidence that Ubc9 is subjected to the post-transcriptional regulation by microRNAs and the miR-30 family, such as miR-30e, negatively regulate Ubc9 expression. In contrast to Ubc9, miR-30e is underexpressed in tumors. Moreover, ectopic expression of miR-30e suppresses cell growth which can be partially reversed by Ubc9. Finally, using luciferase-Ubc9-3'-UTR reporters, we show that Ubc9 is a direct target for miR-30e by interactions with the putative miR-30e binding sites. Therefore, our study suggests that Gam1 and miR-30e may serve as therapeutic agents for cancer treatment by targeting Ubc9.
This dissertation is only
available for download to the SIUC community. Others should contact the
interlibrary loan department of your local library or contact ProQuest's Dissertation Express service.